Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model

Neurochemistry International

Volumn 57, Issue 1, 2010, Pages 16-32

  Park, Bokyung ^a   Yang, Junyoung ^a   Yun, Nuri ^a   Choe, Kwang Min ^a   Jin, Byung K ^b   Oh, Young J ^a  

^a Yonsei University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

6 Hydroxydopamine; Neuronal cell death; Parkinson's disease; Proteomics

Indexed keywords

ACONITASE 2; ADENOSINE KINASE; ADENYLASE KINASE ISOZYME 1; ALPHA SYNUCLEIN; APOLIPOPROTEIN E; BILIVERDIN REDUCTASE A; CALRETININ; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; GLIA MATURATION FACTOR BETA; GLIAL FIBRILLARY ACIDIC PROTEIN DELTA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMATE AMMONIA LIGASE; GLUTATHIONE TRANSFERASE P; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; GLYOXALASE 1; GUANINE DEAMINASE; KARYOPHERIN BETA 1; LIPOCORTIN 5; MITOCHONDRIAL CHAPERONE PROTEIN; NEUROFILAMENT LIGHT POLYPEPTIDE; OXIDOPAMINE; PALMITOYL COENZYME A HYDROLASE; PROHIBITIN; PROTAMINE P2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRANSKETOLASE; TYROSIN 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EXPERIMENTAL RAT; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; RAT; SPATIAL SUMMATION; SUBSTANTIA NIGRA; TEMPORAL SUMMATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; MALE; NEUROBLASTOMA; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEIN INTERACTION MAPPING; PROTEOMICS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REPRESSOR PROTEINS;

RATTUS;

EID: 77953610935     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.04.005     Document Type: Article

References (62)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Samii A., Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G.J., Liu Y., Waichunas D., Montine T.J., Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 2006, 9:293-348.
2. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
3. Ahn C.S., Lee J.H., Reum Hwang A., Kim W.T., Pai H.S. Prohibitin is involved in mitochondrial biogenesis in plants. Plant J. 2006, 46:658-667.
4. Artal-Sanz M., Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol. Metab. 2010, (Epub ahead of print).
5. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
6. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2001, 2:325-334.
7. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. NY Acad. Sci. 2003, 991:120-131.
8. Benit P., Slama A., Cartault F., Giurgea I., Chretien D., Lebon S., Marsac C., Munnich A., Rotig A., Rustin P. Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J. Med. Genet. 2004, 41:14-17.
9. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
10. Boeckmann B., Bairoch A., Apweiler R., Blatter M.C., Estreicher A., Gasteiger E., Martin M.J., Michoud K., O'Donovan C., Phan I., Pilbout S., Schneider M. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 2003, 31:365-370.
11. Bourges I., Ramus C., Mousson de Camaret B., Beugnot R., Remacle C., Cardol P., Hofhaus G., Issartel J.P. Structural organization of mitochondrial human complex I: role of the ND4 and ND5 mitochondria-encoded subunits and interaction with prohibitin. Biochem. J. 2004, 383:491-499.
12. Broussolle E., Thobois S. Genetics and environmental factors of Parkinson disease. Rev. Neurol. (Paris) 2002, 158(1):S11-23.
13. Camougrand N., Rigoulet M. Aging and oxidative stress: studies of some genes involved both in aging and in response to oxidative stress. Respir. Physiol. 2001, 128:393-401.
14. Choi S.H., Joe E.H., Kim S.U., Jin B.K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J. Neurosci. 2003, 23:5877-5886.
15. Choi W.S., Yoon S.Y., Oh T.H., Choi E.J., O'Malley K.L., Oh Y.J. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 1999, 57:86-94.
16. Choudhary J., Grant S.G. Proteomics in postgenomic neuroscience: the end of the beginning. Nat. Neurosci. 2004, 7:440-445.
17. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
18. De Iuliis A., Grigoletto J., Recchia A., Giusti P., Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta 2005, 357:202-209.
19. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
20. Diedrich M., Mao L., Bernreuther C., Zabel C., Nebrich G., Kleene R., Klose J. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics 2008, 8:1266-1275.
21. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
22. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 1992, 32:804-812.
23. Ferrer I., Perez E., Dalfo E., Barrachina M. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease. Neurosci. Lett. 2007, 415:205-209.
24. Fountoulakis M., Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis 2006, 27:1556-1573.
25. Giasson B.I., Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 2003, 114:1-8.
26. Irwin I., DeLanney L.E., Langston J.W. MPTP and aging. Studies in the C57BL/6 mouse. Adv. Neurol. 1993, 60:197-206.
27. Javoy F., Sotelo C., Herbet A., Agid Y. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res. 1976, 102:201-215.
28. Jin J., Hulette C., Wang Y., Zhang T., Pan C., Wadhwa R., Zhang J. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics 2006, 5:1193-1204.
29. Jin J., Meredith G.E., Chen L., Zhou Y., Xu J., Shie F.S., Lockhart P., Zhang J. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:119-138.
30. Klein C., Schlossmacher M.G. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2006, 2:136-146.
31. Lee Y.M., Park S.H., Chung K.C., Oh Y.J. Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxydopamine. Neurosci. Lett. 2003, 352:17-20.
32. Lee Y.M., Park S.H., Shin D.I., Hwang J.Y., Park B.K., Park Y.J., Lee T.H., Chae H.Z., Jin.B.K., Oh T.H., Oh Y.J. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson's disease. J. Biol. Chem. 2008, 283:9988-9998.
33. Licker V., Kövari E., Hochstrasser D.F., Burkhard P.R. Proteomics in human Parkinson's disease research. J. Proteomics 2009, (Epub ahead of print).
34. Liu X.H., Ren Z., Zhan R., Wang X.X., Wang X.M., Zhang Z.Q., Leng X., Yang Z.H., Qian L.J. Prohibitin protects against oxidative stress-induced cell injury in cultured neonatal cardiomyocyte. Cell Stress Chaperones 2009, 14:311-319.
35. McLaughlin P., Zhou Y., Ma T., Liu J., Zhang W., Hong J.S., Kovacs M., Zhang J. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 2006, 53:567-582.
36. Merkwirth C., Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim. Biophys. Acta 2009, 1793:27-32.
37. Mishra S., Murphy L.C., Nyomba B.L., Murphy L.J. Prohibitin: a potential target for new therapeutics. Trends Mol. Med. 2005, 11:192-197.
38. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28:57-87.
39. Nakamura M., Yamada M., Ohsawa T., Morisawa H., Nishine T., Nishimura O., Toda T. Phosphoproteomic profiling of human SH-SY5Y neuroblastoma cells during response to 6-hydroxydopamine-induced oxidative stress. Biochim. Biophys. Acta 2006, 1763:977-989.
40. Nijtmans L.G., Artal S.M., Grivell L.A., Coates P.J. The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell. Mol. Life Sci. 2002, 59:143-155.
41. Nijtmans L.G., de Jong L., Artal Sanz M., Coates P.J., Berden J.A., Back J.W., Muijsers A.O., van der Spek H., Grivell L.A. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000, 19:2444-2451.
42. Ovadia A., Zhang Z., Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 1995, 16:931-937.
43. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
44. Park B., Jeong S.K., Lee W.S., Seong J.K., Paik Y.K. A simple pattern classification method for alcohol-responsive proteins that are differentially expressed in mouse brain. Proteomics 2004, 4:3369-3375.
45. Park B., Oh S.H., Seong J.K., Paik Y.K. A strain-specific alteration of proteomic expression in mouse liver fructose 1,6-bisphosphatase isoforms by alcohol. Proteomics 2004, 4:3413-3421.
46. Peri S., Navarro J.D., Amanchy R., Kristiansen T.Z., et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res. 2003, 13:2363-2371.
47. Periquet M., Corti O., Jacquier S., Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 2005, 95:1259-1276.
48. Pruitt K.D., Katz K.S., Sicotte H., Maglott D.R. Introducing RefSeq and LocusLink: curated human genome resources at the NCBI. Trends Genet. 2000, 16:44-47.
49. Schapira A.H. Mitochondrial disorders. Curr. Opin. Neurol. 1997, 10:43-47.
50. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
51. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 1998, 44:S89-98.
52. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996, 50:275-331.
53. Sherer T.B., Betarbet R., Greenamyre J.T. Environment, mitochondria, and Parkinson's disease. Neuroscientist 2002, 8:192-197.
54. Theiss A.L., Idell R.D., Srinivasan S., Klapproth J.M., Jones D.P., Merlin D., Sitaraman S.V. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 2007, 21:197-206.
55. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
56. Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., Quack G., Cenci M.A. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced Dyskinesia. J. Neurochem. 2007, 102:395-1409.
57. van der Walt J.M., Nicodemus K.K., Martin E.R., Scott W.K., et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 2003, 72:804-811.
58. Van Laar V.S., Dukes A.A., Cascio M., Hastings T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 2008, 29:477-489.
59. Werner C.J., Heyny-von Haussen R., Mall G., Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 2008, 6:8.
60. Xenarios I., Rice D.W., Salwinski L., Baron M.K., Marcotte E.M., Eisenberg D. DIP: the database of interacting proteins. Nucleic Acids Res. 2000, 28:289-291.
61. Waragai M., Wei J., Fujita M., Nakai M., Ho G.J., Masliah E., Akatsu H., Yamada T., Hashimoto M. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 345:967-972.
62. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson disease. Am. J. Clin. Pathol. 2008, 129:526-529.